In agreement with the existing policy the research board and Radboud Center for Oncology have decided to continue with the mandatory internal review procedure for KWF grant applications.The internal review of KWF project proposals is meant to improve the quality of the proposals and thereby raising the chance of awarding. The internal review procedure is in place for all types of projects granted by KWF. Please be aware the pre-application deadline in case of Infrastructure initiatives.
Please find here the schedule for the internal KWF review procedure. We kindly ask you to adhere to it.
Important internal deadlines are:
- 4 February 2019: Opens pre-submission Infrastucture initatives
- 6 March 2019: KWF deadline pre-submission Infrastucture initatives
- 10 April 2019: Registration of new application
- 24 April 2019: Internal submission of full application
- 5 June 2019 (12:00): KWF deadline
Information on the KWF Program Research & Implementation can be found on the KWF website.
Related news items
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Dutch Kidney Foundation Innovation grant for Tom Nijenhuis14 May 2019
Tom Nijenhuis, theme Renal disorders, received this grant for his research project “Salt supplementation in Gitelman syndrome: A simple intervention using an innovative N-of-1 trial approach”.read more
Algorithm calculates the presence and aggressiveness of prostate tumors14 May 2019
A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more